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Available online xxxxThe Congenital Disorders of Glycosylation (CDG) are an expanding group of genetic disorderswhich encompass a
spectrum of glycosylation defects of protein and lipids, including N- & O-linked defects and among the latter are
the muscular dystroglycanopathies (MD). Initial screening of CDG is usually based on the investigation of the
glycoproteins transferrin, and/or apolipoprotein CIII. These biomarkers do not always detect complex or subtle
defects present in older patients, therefore there is a need to investigate additional glycoproteins in some
cases. We describe a sensitive 2D-Differential Gel Electrophoresis (DIGE) method that provides a global analysis
of the serum glycoproteome. Patient samples from PMM2-CDG (n=5), CDG-II (n=7),MD and known complex
N- & O-linked glycosylation defects (n= 3) were analysed by 2D DIGE. Using this technique we demonstrated
characteristic changes in mass and charge in PMM2-CDG and in charge in CDG-II for α1-antitrypsin, α1-
antichymotrypsin, α2-HS-glycoprotein, ceruloplasmin, and α1-acid glycoproteins 1&2. Analysis of the samples
with known N- & O-linked defects identiﬁed a lower molecular weight glycoform of C1-esterase inhibitor
that was not observed in the N-linked glycosylation disorders indicating the change is likely due to affected
O-glycosylation. In addition, we could identify abnormal serum glycoproteins in LARGE and B3GALNT2-deﬁcient
muscular dystrophies. The results demonstrate that the glycoformpattern is varied for some CDG patients not all
glycoproteins are consistently affected and analysis of more than one protein in complex cases is warranted. 2D
DIGE is an idealmethod to investigate the global glycoproteome and is a potentially powerful tool and secondary
test for aiding the complex diagnosis and sub classiﬁcation of CDG. The technique has further potential in
monitoring patients for future treatment strategies. In an era of shifting emphasis from gel- to mass-spectral
based proteomics techniques, we demonstrate that 2D-DIGE remains a powerful method for studying global
changes in post-translational modiﬁcations of proteins.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Congenital Disorders of Glycosylation
Dystroglycanopathies, 2D DIGE
C1-esterase inhibitor
Glycoproteome
α1-Antitrypsin1. Introduction
Congenital Disorders of Glycosylation (CDG) are a groupof rare inborn
errors of metabolism and include some forms of dystroglycanopathies.
They are an expanding family of predominantly autosomal recessiveel expression; CDG, Congenital
r dystrophy; IEF, isoelectric fo-
ic golgi.
of Metabolism, Great Ormond
UK.
wood).
. This is an open access article undermulti-systemic disorders [1]. Since glycosylation is a complex biological
process involving many pathways, any defect may result in defective
glycosylation. Hence there are N60 distinct disorders identiﬁed to date
[2,3]. These are sub-grouped into defects of protein N-glycosylation,
protein O-glycosylation, lipid glycosylation, GDP-anchor glycosylation
and multiple glycosylation defects [4]. CDG have a very broad range of
clinical symptoms that can involve many organs with a wide spectrum
of clinical severity [5] making initial clinical assessment challenging.
The most common form of CDG results primarily from defects in the
phosphomannomutase 2 gene (termed PMM2-CDG) this disrupts
early steps in the glycan assembly and attachment of glycans to proteins
resulting in the complete absence of N-linked glycans on somethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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result of defective remodeling of glycans resulting in truncated and ab-
normal glycan structures (microheterogeneity). Several CDG-II causing
mutations are in genes involved in the Conserved Oligomeric Golgi
(COG) complex [6].
O-glycosylation is an even more complex process [7]. The clinical
spectrumwithin a single disorder and among the different inborn errors
of O-glycan metabolism is vast and the disorders described to date
may represent only a subset [8]. One such class of O-linked CDG are
the dystroglycanopathies [9]. Alpha dystroglycanopathy is a large glyco-
protein of approximately 156 kDa in skeletal muscle and is heavily N
and O-glycosylated as well as O-mannosylated [10]. Many of the
described mutations for muscular dystrophy affect the O-glycosylation
pathways for the biosynthesis of α-dystroglycan and new types of
CDG have been described that result in defects in the O-mannosyl
glycosylation pathway [11–14].
Traditionally the isoelectric focusing (IEF) pattern of serum transferrin
is used to detect disorders of protein N-glycosylation and is usually the
ﬁrst step in screening for CDG. Transferrin is a 79 kDa serum glycoprotein
with two N-linked glycans and is highly abundant in serum. A positive
transferrin result needs to be followed up by further enzyme and/or
genetic testing to identify the speciﬁc type of CDG. A similar IEF test to
help diagnose O-linked disorders is performed on apolipoprotein-CIII
which has a single O-linked glycan which only captures abnormalities
of core-1mucin type O-glycosylation [15]. Both of these tests require
specialist laboratories to run and interpret the results for a conclusive
diagnosis.
While serum transferrin IEF has proven to be a useful test for defec-
tiveN-glycosylation [5], it only identiﬁes differences in charge and lacks
information on changes inmolecularweight (MW). In addition, second-
ary glycosylation disorders including galactosaemia, hereditary fructose
intolerance, bacterial infections [16] and transferrin polymorphisms
must be excluded before considering a diagnosis of CDG. Othermethods
of CDG investigation include isoelectric focusing of other glycoproteins
or investigation of the total glycan proﬁle from glycans removed
from the glycoproteins using PNGase F digestion and MALDI analysis
[17]. There are a number of suspected CDG cases which do not have
altered transferrin IEF proﬁles or for whom traditional tests provide
inconclusive results. Therefore a secondary test to conﬁrm the frontline
IEF tests currently used for complex cases is needed. Therefore we
have optimised the 2-Dimensional –Difference Gel Electrophoresis
(2D-DIGE) method [18] to examine the global serum glycoproteome.
2D-DIGE is an ideal method to investigate changes in post-translational
modiﬁcations of proteins since multiple samples can be run simulta-
neously, eliminating gel-to-gel variations and allowing for direct overlaid
comparison. This is particularly useful in interpreting subtle or complex
CDG type II cases in which the changes in IEF may be subtle. The ability
to include conﬁrmed PMM2-CDG and CDG-II samples as internal
standards makes interpretation more reliable. Subtle changes in charge
and molecular weight can also be observed allowing the detection of a
range of defects in post-translational modiﬁcations including those of
glycosylation that traditional 2D PAGE methods would not detect. To
our knowledge this is the ﬁrst time this technique has been applied to
such a large cohort of diverse CDG patient samples. We observed
glycoform proﬁle changes forN-linked and O-linked disorders in looking
at various N-glycosylated glycoproteins such as α1-antitrypsin, α-1-
antichymotrypsin, and α1-acid glycoproteins 1 & 2 and N- and O-
glycosylated α2-HS-glycoprotein and C1-esterase inhibitor.
2. Materials and methods
2.1. Patient samples
The studywas approved by the local NHSResearch Ethics committee
(London-Bloomsbury) ref: 12/LO/0905. Samples used in this studywere
anonymized surplus serum remaining from routine diagnostic analysisand were stored and used for the purpose of improving methods for
CDG diagnosis. Serum samples were obtained after separation from
the cells by centrifugation (3000 g/10 min). All samples were stored
frozen at−80 °C prior to analysis.
Patient age-range at sampling was between four months and ﬁve
years. CDG patients included were diagnosed and treated at Great
Ormond Street Hospital Metabolic Unit. Muscular dystrophy patients
were diagnosed by the Dubowitz Neuromuscular Centre team at Great
Ormond Street Hospital and previously, at the Hammersmith Hospital,
London.
Table 1 summarises the disease samples used in this study and
details the defect(s) where known. Brieﬂy, ﬁve genetically conﬁrmed
PMM2-CDG and seven CDG patients with a type II transferrin IEF
pattern were included, as was serum from three muscular dystrophy
patients; one with LARGE mutation; one with a B3GALNT2 mutation
and one an unexplained dystroglycanopathy. Three patients with N- &
O-linked glycosylation defects and two patients with inconclusive
transferrin or apolipoprotein CIII IEF proﬁles and with suspected CDG
disorders were analysed to test the method developed. Ten age
matched anonymized control samples were selected from surplus
serum of patients visiting GOSH for other purposes.
2.2. 2-Dimensional difference gel electrophoresis (2D DIGE)
For each sample 40 μl of serum was depleted for albumin and IgG
using a ProteoPrep Albumin/IgG Depletion Kit (Sigma-Aldrich, Dorset,
U.K.). Depleted protein was eluted in 50 mM ammonium bicarbonate
buffer pH 7.8 and assayed for protein concentration using the
bicinchoninic acid assay kit (Sigma-Aldrich, Dorset, U.K.). Protein was
aliquoted into required amounts and freeze dried.
Freeze-dried serum protein (50 μg) was labeled with Cy-Dye DIGE
Fluor minimal dye (GE Healthcare) at a concentration of 200 pmol of
dye/50 μg of protein. Samples were labeled with Cy3, Cy5, or Cy2. Con-
trol protein consisted of pooled sera from ﬁve normal subjects, this was
used as the internal standard run on all gels and represent the ‘normal’
glycoform proﬁle to compare patient samples with. All three labeled
samples, (pooled control and two patients), were combined and
resolved on one gel. Combined samples were added to IPG strip rehy-
dration buffer (7 M Urea, 2 M Thiourea, 2% CHAPS, 50 mM DTE and 1%
4–7 IPG buffer) with pH 4–7 or 3–6.5 immobiline drystrips. IEF strips
were left at room temperature for 12 h to rehydrate prior to analysis
and run the following day on an IPG multiphor (GE Healthcare). Each
IEF strip was focused for between 90 and 100,000 V h. After IEF all strips
were ﬂash frozen using liquid nitrogen and stored at−80 °C. IEF strips
were re-equilibrated prior to separation by PAGE using amethod previ-
ously described [19]. PAGE was carried out on 10% and 15% acrylamide
gels using piperazine diacrylamide as the cross-linker to improve the
resolution of proteins. Gels were scanned in a Typhoon Variable Mode
Imager (GE Healthcare) using appropriate lasers and ﬁlters with
photomultiplier (PMT) voltage between 550 and 600 V. 2D DIGE gel
images were analysed using Progenesis Same Spots software version
4.2 (Non-Linear Dynamics, Ltd). All protein identities were conﬁrmed
by in-gel digestion of proteins.
2.3. In-gel proteolytic digestion and identiﬁcation of proteins
In-gel digestion of proteins was performed according to published
methods [19,20]. All analyses were performed as described previously
[21] using a nano-Acquity UPLC and QTOF Premier mass spectrometer
(Waters Corporation, Manchester, UK).
Data were analysed using ProteinLynx Global Server (PLGS) version
2.4 (Waters Corporation, Manchester, UK) with a downloaded Uniprot
Human Proteome database. Search settings allowed a minimum three
ionmatches per peptide, seven ionmatches and three peptidesmatches
per protein. Modiﬁcations taken into account included up to three
missed cleavage sites for trypsin with carboxymethylated cysteine as a
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57W.E. Heywood et al. / Molecular Genetics and Metabolism Reports 7 (2016) 55–62ﬁxed modiﬁcation and oxidation of methionine as a variable modiﬁca-
tion. Only proteinswith a PLGS score N95% conﬁdencewere considered.
Mass spectrometry data is provided in the Supplementary data Table S1.
2.4. Western Blot analysis
Dilutions of serum samples weremade in Phosphate Buffered Saline
(PBS), pH 7.2 and the equivalent of 0.75 μl of serum was separated by
10% SDS-PAGE under reducing conditions. Proteins were blotted onto
Hybond-LFP PVDF membrane (GE Healthcare, Amersham, UK). Blots
were blocked for 1 h in 5% w/v non-fat dried milk in PBS. Membranes
were incubated for 2 h at room temperaturewith 1 μg/mlmousemono-
clonal antibody to C1 esterase inhibitor (Abcam plc, Cambridge, UK), at
a 1:2000 dilution. Blots were washed six times for 10 min with 0.1%
Tween 20 in PBS before being incubated for 1 h with anti-mouse HRP
labeled secondary antibody 1:2500 dilution. Blots were washed and
dried and subjected to ECL (GE Healthcare, Amersham UK).
3. Results and discussion
3.1. Altered glycoproteins observed in N-linked glycosylation disorders
The initial 2D DIGE experiment over the pH range 4–7 revealed clear
changes in charge and mass for transferrin, α1-antitrypsin, α1-
antichymotrypsin, α2-HS-glycoprotein and ceruloplasmin when patient
samples were compared to that of the pooled control (Fig. 1).
Analysis of the 2D-DIGE gel over the pH range 4–7 demonstrated
that the proteins observed displaying themost changes in glycosylation
were observed in those glycoproteins observed in the 3–5 pH range.
Therefore, a high resolution and targeted 2D-DIGE method over pH
range 3–5.6 was used in all subsequent analyses. Using this technique
proteins identiﬁed as being more signiﬁcant diagnostically and more
subtle markers of inborn errors of glycosylation included α1-
antitrypsin, α1-antichymotrypsin, α2-HS-glycoprotein, C1-esterase
inhibitor and ceruloplasmin. Changes in transferrin were observed in
the initial analysis in the 4–7 pH range, however after optimising the
conditions to look at the 3–5 pH range we were no longer able to
observe transferrin as the pI for transferrin is 6.5–7. As transferrin
proﬁles had already been performed and were used for the selection
of the samples the presence of transferrin in the global proﬁle analysis
was deemed not essential.
3.2. Characteristic changes observed in PMM2-CDG and CDG-II
3.2.1. α1-Antitrypsin is a glycoprotein with 3 N-linked glycans
Analysis over the pH range 3–5.6 demonstrated signiﬁcant and con-
sistent shifts in pI of the α1-antitrypsin glycoforms for all PMM2-CDG
and CDG-II patients (Fig. 2).
Isoelectric focusing of serumα1-antitrypsin leads to the detection of
eight bands or glycoforms, known as α1-antitrypsin glycoforms M1 to
M8 (anodal-low pH to cathodal-high pH). The bands M4 and M6 are
the most abundant glycoforms, making up 40% and 34% of the total
serum α1-antitrypsin, respectively, whereas M3 and M5 are present
in only trace amounts. All CDG patients tested exhibited a charge shift
of the M4 andM6 glycoforms ofα1-antitrypsin as described previously
[19]. These reduced molecular weight glycoforms were only observed
in the PMM2-CDG patients. Analysis of individual α1-antitrypsin
glycoforms shown in Fig. 2 were performed using the Progenesis
‘Same Spots’ software (Non Linear Dynamics). Comparison of the spot
intensities revealed the most abundant glycoform of α1-antitrypsin to
be M4 in a normal proﬁle but in all CDG cases the most abundant was
the lesser charged M6 glycoform. This data indicates in all the CDG
cases, the presence of truncated glycans resulting in a shift of each
glycoform to a higher pI value due to loss of the negatively charged sialic
residues. Alpha-1-antitrypsin was also the consistently better glycopro-
tein biomarker for distinguishing PMM2-CDG from CDG-II using the
Fig. 1. Representative 15% 2D PAGE of albumin and IgG depleted serum. Highlighted proteins that had detectable changes in charge andmass in PMM2-CDG and CDG-II samples. The area
deﬁned by dashed lines equates to the optimised higher resolution area for glycoform analysis which was in the 3–5.6 pH range with a 10% acrylamide PAGE for proteins 40–200 kDa.
58 W.E. Heywood et al. / Molecular Genetics and Metabolism Reports 7 (2016) 55–62presence of lower molecular weight glycoforms. The two samples of
unknown or suspected CDG-II cases (patients A and Z) which gave in-
conclusive transferrin IEF results both showed a charge reduction for
α1-antitrypsin which was not always observed with transferrin. 2D
DIGE analysis revealed lowMWglycoforms ofα1-antitrypsin indicating
PMM2-CDG. This data indicates that α1-antitrypsin is a more sensitive
protein or biomarker for diagnosing PMM2-CDG cases than transferrin.3.2.2. Ceruloplasmin
Ceruloplasmin is a glycoprotein with 6 N-linked glycans and is in-
volved in the transport of copper in serum. 2D DIGE analysis revealed
ceruloplasmin to be characteristically altered in PMM2-CDG and CDG-
II (Fig. 3).Fig. 2. 2D DIGE analysis of alpha-1 antitrypsin. Upper panels show overlaid images ofα1-antitr
M4andM6 glycoforms ofα1-antitrypsin are readily detectable in the PMM2-CDGand are show
Themiddle panel shows a 3D schematic of the above images and highlights quantitative change
color in this ﬁgure legend, the reader is referred to the web version of this article.)As with other glycoproteins a charge shift is observed in the
glycoforms for these patients. The difference between PMM2-CDG and
CDG-II can be further differentiated by the degree of charge shift for ce-
ruloplasmin. PMM2-CDG cases showed a profound shift to the cathode
or higher pI range (Fig. 3) whilst it is much more subtle in CDG-II. This
shift was more pronounced than that observed in α1-antitrypsin and
probably results from the greater number of glycans present on the
molecule. In PMM2-CDG there appears to be a gradual mass reduction
in the lesser charged glycoforms. However, this was a more subtle
change in PMM2-CDG than the distinct lower mass glycoforms which
were observed for α1-antitrypsin and transferrin. In addition, a signiﬁ-
cant reduction in the concentration of ceruloplasmin was observed in
the PMM2-CDGpatients (Fig. 3). Thismay be due to the larger size of ce-
ruloplasmin which migrates as 133 kDa on this percentage gel (Fig. 1)ypsin from control (pink) and PMM2-CDG and CDG-II patients (green). Underglycosylated
n in green. Shifts in charge andmass of the glycoforms of the protein can be easily observed.
s in theα1-antitrypsinM4 andM6glycoformpeaks. (For interpretation of the references to
Fig. 3. 2D DIGE analysis of ceruloplasmin in control, PMM2-CDG and CDG-II. Representative overlaid (top panels) and 3D images of ceruloplasmin illustrating typical changes observed in
CDG-II and PMM2-CDG. The overlaid image shows normal pink and overlaid with either CDG as green. CDG-II patients show a subtle charge change as typically seen with many serum
glycoproteins which is highlighted by the red ring. The overall concentration, charge and mass change is signiﬁcantly affected in PMM2-CDG and indicated by the red rings either side
of the ceruloplasmin chain. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
59W.E. Heywood et al. / Molecular Genetics and Metabolism Reports 7 (2016) 55–62and the inability to fully differentiate proteinmolecular weight changes
in a gel at thismass range. Previous 2D-PAGE studies have not described
altered ceruloplasmin proﬁles in CDG and to our knowledge this is the
ﬁrst time it has been reported. Detection has probably been enhanced
by the removal of albumin which could have obscured ceruloplasmin
in earlier serum 2D PAGE studies.
3.2.3. Other glycoproteins demonstrating changes in PI/molecular weight in
CDG
Alpha 1 acid glycoproteins 1 & 2 are observed on a 2D-DIGE as 2 pro-
tein spots that are very close to one another (Supplementary Fig. S1 panel
B). However, this did not affect the identiﬁcation of changes observed in
PMM2-CDG patients which demonstrated a lower molecular weight
glycoform whilst analyses of the CDG-II patient serum demonstrating
the presence of an extra isoform of higher pI value. This followed the
classical shift in pI and/or molecular weight of a glycoprotein expected
and observed due to defects in either micro- or macroheterogeneity, as
observed in PMM2-CDG and CDG-II patients, respectively. Alpha 1-
antichymotrypsin andα2-HS-glycoprotein appear on a 2D gel as 2 chains
of similar glycoforms and have similar molecular weights (Supplementa-
ry Fig. S1 panel A). Although changes in glycosylation were indicated in
each or either glycoprotein it is difﬁcult to say with certainty what the
speciﬁc changes are due to this close proximity andmakes interpretation
difﬁcult hence these glycoproteins not ideal to use for assessment of
altered glycosylation by this method hence they have been indicated as
variable changes in Table 1.
3.3. Analysis of serum from patients with both conﬁrmed N- & O-linked
CDG
Most proteins present in serumare primarilyN-linked glycoproteins
and the only glycoproteins with O-linked glycans, that can be observed
with conﬁdence using 2D DIGE in the optimal pH range 3–6 were α2-
HS-glycoprotein (2 complex N-linked glycans and 2 O-linked glycans)
and C1 esterase inhibitor which has 7 N-linked glycans (one complex
N glycan) and 8 O-linked glycans. Therefore we suspected potential
O-linked disorders could be indicated by changes in glycoforms of
these proteins. To investigate this we analysed samples from patients
with genetically deﬁnedN- & O-linked disorders or for whom a positive
apo-CIII IEF result had been reported previously (Table 1).C1 esterase inhibitor shows only a very small molecular weight
change for what would be predicted in PMM2-CDG (Supplementary
Fig. S1 panel Cb) However as described previously, it is very difﬁcult
to conﬁrm at this very low pI range due to breakdown of IEF resolution
therefore C1 esterase inhibitor is not an ideal glycoprotein to assess
N-glycosylation. However patients S, L, J and K did show a much
lower molecular weight glycoform (Fig. 4). Fig. 4 shows representative
images of C1 esterase inhibitor from a 2D DIGE image of patients with
MAN1B1 deﬁciency and a LARGE mutation. This glycoform was low in
abundance and analysis by in-gel digestion and LC-MS/MS conﬁrmed
this proteinwas C1 esterase inhibitor. Further conﬁrmationwas obtain-
ed using western blotting for C1 esterase inhibitor performed on
PMM2-CDG and several conﬁrmed muscular dystrophy patient serum
samples (Fig. 4B). The Western blot data conﬁrmed the presence of a
smaller MW glycoform (appx 5–10 kDa less) in PMM2-CDG serum as
observed by 2D DIGE. An even smaller and fainter MW glycoform of
appx 10–20 kDa less was observed for patient L and in patient M with
an unknown mutation. Proﬁles of C1 esterase inhibitor for other MD
patient samples with known mutations were however observed to be
normal (Fig. 4B). The smaller C1 esterase inhibitor glycoform observed
in patient L by Western blotting conﬁrmed the identity of the lower
molecular weight glycoform observed by 2D DIGE. This glycoform is
not observed in typical PMM2-CDG and CDG-IIx samples and has only
been observed in patients with known affected N- & O-linked glycosyl-
ation and apo-CIII positive results (patients S, & K). This indicates
strongly that this C1 esterase inhibitor glycoform is present due to
altered O-glycosylation.
Patient J was diagnosed with a UDP galactose transporter deﬁciency
conﬁrmed by genetic studies [22], which is known to result in reduced
transport of galactose to the Golgi apparatus and galactose is required
for bothN- and O-glycan assembly. Analysis of transferrin IEF presented
with a potential type II pattern. A combined N- & O-linked disorder was
suspected but the apo CIII IEF analyses were not conclusive. Using 2D
DIGE we were able to conﬁrm that N-linked glycosylation was affected
(Table 1), with pI shifts seen typically for CDG type II patterns in α1-
antitrypsin, ceruloplasmin and α1-antichymotrypsin. In addition, a
lower molecular weight glycoform of C1 esterase inhibitor was also ob-
served indicating an additional defect in O-glycosylation. Our analysis
shows glycoform proﬁling of other proteins in particular C1 esterase in-
hibitor reveals a combined defect in N- & O-glycosylation is detectable
using 2D DIGE analyses of the whole glycoproteome and highlights
Fig. 4. 2DDIGE (A& C) andWestern Blot (B) analysis of muscular dystrophy patients. Panel A shows 2DDIGE gel images of C1 esterase inhibitor in control, Patient Swith anMAN1B1N- &
O-linkeddisorder and patient Lwith a LARGEmutation. A lowmolecularweight glycoform is observed in both patients. This particular lowermolecularweight glycoform is not observed in
N-linked CDG disorders. Panel B shows 1D western blot images of C1 esterase inhibitor for PMM2-CDG where a lower molecular weight form is observed. This glycoform indicates the
degree ofmass change for C1 esterase inhibitor in anN-linked only disorder. However in themuscular dystrophy patient with a LARGEmutation, an even greater lowermolecular weight
band is observed (red arrow) aswell as in anMDpatient with an unknownmutation. Nomolecular weight glycoforms are observed for otherMDmutations FKRP and POMGNT1. Panel C
shows an overlaid 2DDIGE image ofα1-antichymotrypsin (top chain) andα-2-HS-glycoprotein (bottom chain) of a patient Y anMD patientwith a B3GALNT2mutation. No changeswere
observed for any N-linked proteins in patient Y however a clear lower molecular weight glycoform of α2-HS-glycoprotein is seen. α2-HS-glycoprotein is N- & O-glycosylated indicating
that O-glycosylation maybe affected in this patient. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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second tier test in difﬁcult to interpret and complex cases.
Patient K is a cutis laxa patient with a defect in the ATP6V0A2 gene
which forms part of the proton channel of V-ATPases [23]. Defects in
this proton pump affect the pH of the COG complex which is vital
for many functions including N- and O-glycosylation. Changes in the
N-linked glycoproteins, ceruloplasmin and α1-antichymotrypsin (Table
1) but not for α1-antitrypsin were observed, thus again highlighting
the importance of investigating more than one glycoprotein. Analysis
of C1 esterase inhibitor revealed the presence of the smaller molecular
weight glycoform indicating affected O-glycosylation.
Patient S had aMAN1B1 (alpha-1,2-mannosidase) defect, which has
been reported to be localized to the Golgi complex [24]. The precise
mechanism of the defect is yet to be elucidated but is thought to affect
the glycoprotein synthesis quality control process. Patient S indicated
a type II transferrin IEF proﬁle and a positive apo CIII proﬁle. 2D DIGE
analysis revealed a CDG type II pattern for α1-antitrypsin, ceruloplas-
min but inconclusive observations for α1-antichymotrypsin and α2-
HS-glycoprotein. Affected O-glycosylation was able to be conﬁrmed by
the presence of the smaller C1 esterase inhibitor glycoform. (Table 1,
Fig. 4).
This group of threeN- &O-linked disorders overall represent 2 defects
in the mechanisms of the assembly of N- and O-linked glycans (UDP-ga-
lactose transporter and MAN1B1 defects) whilst the ATP6V0A2 cutis
laxa defect disturbs the optimal environment required for glycosylationin the golgi and hence affects the function of many proteins involved in
glycosylation. The serum glycoproteins affected as shown by 2D DIGE
do suggest a difference in the way the glycosylation is affected between
these classes of disorder as the UDP-galactose transporter and MAN1B1
deﬁciencies show the same pattern as seen in other CDG-II defects but
with additional defective O-linked glycosylation. The proﬁle of the
cutix laxa patient shows the same apart from a normal proﬁle for α1-
antitrypsin indicating a subtler effect. This observation may be useful
in the future for initial investigations of complex CDG cases where in-
vestigatorsmay look towards defects in genes in either glycan assembly
or genes involved in controlling external factors needed for efﬁcient
glycosylation (such as golgi pH).
3.4. The dystroglycanopathies
Muscular dystrophy patient L had been diagnosed previously with a
compound heterozygous mutation in the LARGE gene. The exact
function of the LARGE gene remains undetermined but recent reports
indicate that it encodes a bifunctional protein with xylosyl- and
glucuronyltransferase activities and is required for O-mannosylation
of α-dystroglycan. LARGE is involved in the synthesis of complex N-
glycan andmucin typeO-glycans [25,26]. 2DDIGE analysis demonstrated
a potential PMM2-CDG type proﬁle. Curiously α1-antitrypsin appears to
have lower molecular weight glycoforms present but a charge change
was not observed. Lower molecular weight glycoforms were observed
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suggesting altered N-glycosylation but with a very subtle phenotype
compared with PMM2-CDG patients. As discussed previously, and
shown in Fig. 4, patient L presented with the lower molecular weight
C1 esterase inhibitor glycoform conﬁrming affected O-glycosylation.
Our analysis of the serum glycoproteome of the LARGEmutation patient
conﬁrms that many glycoproteins are glycosylated abnormally but not
necessarily in a characteristic fashion as typical PMM2-CDG and CDG-II.
Patient Y had B3GALNT2 mutation. Mutations in this gene were
recently identiﬁed in a group of muscular dystrophy patients with
severe structural brain involvement. B3GALNT2 transfers N-acetyl
galactosamine (GalNAc) in a b-1,3 linkage to N-acetyl glucosamine
(GlcNAc) and the speciﬁc role of this enzyme in α-dystroglycan glyco-
sylationwas recently described [27]. As with patient L, 2DDIGE analysis
also did not reveal a proﬁle typical to PMM2-CDGor CDG-II with patient
Y. However a subtle anodic charge shift and increased MW change was
observed forα1-antitrypsinwhich could potentially be due to increased
fucosylation [28]. Other glycoproteins appeared not to be affected apart
from α2-HS-glycoprotein which exhibited a distinct reduction in
molecular weight (Fig. 4C). Unfortunately the analysis of C1 esterase in-
hibitorwas inconclusive for patient Y. Asα2-HS-glycoprotein is the only
other O-glycosylated protein in the pH range investigated it is possible
the reduced MW form observed in this patient may be due to affected
O-glycosylation.
4. Discussion and conclusions
This work does not propose replacement of current techniques for
the diagnosis of CDG in routine practice (serum IEF of transferrin and
apo CIII). However, in complex cases or those with IEF patterns which
are difﬁcult to interpret, 2D DIGE has been demonstrated to be an effec-
tive tool for the investigation of not only PMM2-CDG, CDG-II and com-
bined N- & O-linked disorders but also for the investigation of some
muscular dystrophies. Analysing multiple glycoproteins has revealed
subtle glycosylation effects that may only be identiﬁed on lower abun-
dant glycoproteins. For the muscular dystrophies, baseline tests so far
mainly rely on muscle biopsy to stain for α-dystroglycan a method
that could potentially be complemented by glycoproteome proﬁling.
MALDI ToF MS is a method commonly used to determine the
structure of glycans in CDG patients [29] but is typically used only for
N-linked glycans. Mass spectrometry has also been applied to the
analysis of glycopeptides which can provide information on both site-
speciﬁc micro and macroheterogeneity [30]. However, development of
an MS based test that could be used to proﬁle multiple N-linked glyco-
peptides and O-linked glycopeptides is challenging. This is primarily
due to the size of glycopeptideswhich are too large formost commercial
mass spectrometers used in chemical pathology laboratories whose
upper mass range is around 2000 Da. The advent of electron-transfer
dissociation (ETD), which fragments peptides by a different pathway
compared with conventional collision induced dissociation (CID)
leaving peptide side-chains (including modiﬁcations such as glycans)
intact, is promising and analysis of intact O-glycopeptides has been
reported [31]. However, the ability to detect under glycosylated O-
glycopeptides in a complex mixture will remain challenging as often
the under-glycosylated species are present in low levels in CDG patients
therefore analysis of intact glycoproteins by 2D DIGE may be more
informative and cost effective.
Analysis of suspected CDG samples using 2D DIGE helped conﬁrm
two patients with typical PMM2-CDG proﬁles (patients A and Z, Table
1). We were also able to show seven patients had normal serum
glycoform proﬁles and were eliminated from having a defect in N- or
O-linked glycosylation (data not shown).
The analysis of 5 patientswithmolecular genetically conﬁrmeddiag-
nosis of N&O linked CDGand dystrogycanopathies reveals the potential
of the method for looking at complex cases of CDG related to different
glycosylation pathways. To identify and conﬁrm recognizable patternsfurther rare complex cases are required to be analysed. 2D DIGE has
primarily been used for global differential protein expression and to
our knowledge this is the ﬁrst application of this method to the investi-
gation of glycosylation disorders. Previous studies have utilized silver
stained 2D gels to investigate large charge shifts and MW changes. By
using 2D DIGE, where control and patient samples can be analysed
simultaneously on the same gel, we have been able to observe more
subtle changes in other glycoproteins with higher resolution, which
has not been reported previously. The technique was improved further
by the inclusion of an initial depletion step removing the abundant
serum proteins albumin and immunoglobulin G and the selection of a
high resolution IEF range for candidate marker glycoporoteins. The
incorporation of a depletion step was able to reveal ceruloplasmin as a
good marker for N-linked glycosylation which has also not been
described previously.
In summary, serum glycoform proﬁling by 2DDIGE has proven to be
a second tier useful technique in assessing defective glycosylation. α1-
antitrypsin appears to be the ideal protein to distinguish PMM2-CDG
and CDG-II patients however as demonstrated on more than one occa-
sion in this study, reduced glycosylation of individual proteins between
patients is variable and ideally more than one glycoprotein should be
assessed at screening. This method can also not just be applied to
serum but also other CDG tissues to identify affected glycoproteins.
[32]. Characterising a glycoproteome proﬁle of patients prior to and on
treatment will help to get a better understanding in the changes of a
plethora of glycoproteins and related clinical observations. 2D DIGE
could become a very useful and an informative tool for monitoring the
effect of current and future treatments for CDG.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgmr.2016.03.002.
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